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INTRODUCTION 
The 21st century is an era of tremendous 
development and innovation in all aspects of life 
in general and in the field of technology in 
particular which has made living much more 
comfortable on one side but on the other side 
gifted many life style related diseases. Today’s 
life style mainly includes faulty food habits, 
minimum physical exercise, maximum mental 
and intellectual exercise with stress, anxiety and 
depression resulting into various abnormalities 
in body composition, one of such gift is 
Dyslipidemia. Particularly the unhealthy food 
habits like intake of fast food, convenience food, 
processed food, high calorie food and irregular 
timings of meals with sedentary life style is the 
foremost cause for Dyslipidemia. Its prevalence 
is increasing, more over is a potential signal for 
unrecognized comorbidities like Obesity, 
Metabolic syndrome, Diabetes mellitus, 
Hypertension, Cardio vascular disease etc., [1] 
Among the lifestyle disorders 
Dyslipidemia is the disorder of lipoprotein 
metabolism manifested by elevation of the 
total cholesterol the bad low density lipoprotein 
(LDL) cholesterol and the triglyceride 
concentrations and a decrease in the good high 
density lipoprotein (HDL) cholesterol 
concentration in the blood.  
Dyslipidemia is widely regarded as a 
major risk factor for coronary heart disease 
(CHD) and atherosclerotic cardiovascular 
disease (ASCVD); for every 1% increase in 
cholesterol level there is 1-2% increase in the 
incidence of CHD. Death in female due to CHD is 
more than all cancer combined. The global 
Dyslipidemia one of the life style disorder due to the today’s faulty life style. It may be 
manifested by elevation of the total cholesterol the bad low density lipoprotein (LDL) 
cholesterol and the triglyceride concentrations and a decrease in the good high density 
lipoprotein (HDL) cholesterol concentration in the blood. Dyslipidemia is widely regarded 
as a major risk factor for coronary heart disease (CHD) and atherosclerotic cardiovascular 
disease (ASCVD). Every 1% increase in cholesterol level there is 1-2% increase in the 
incidence of Coronary Heart Disease. 
Lipids can be correlated to that of Medo Dhatu. According to the scattered references 
Dyslipidemia can be correlated to Medo Dosha and subsequently as Medoroga. The 
treatment principles mainly includes Samshodhana Chikitsa (Bio cleansing), where as in 
modern statins are first choice of drug.  
Looking into the adverse reactions and the limitations in the modern medication clinical 
trial was carried out in 30 patients having Dyslipidaemia. Lekhana Basti was administered 
and the effect of treatment on the complete lipid profile i.e., Serum cholesterol, 
Triglycerides, HDL, S.LDL, VLDL was assessed after the treatment and follow up. As Basti 
Karma is best treatment for correction of Vata Dosha, which are the basic factors involved in 
the pathogenesis of Medoroga. Statistical analysis using ANOVA and paired t test showed 
highly significant result in the lipid profile after the treatment and follow up. 
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burden of disease study has estimated that 
cardiovascular disorders are currently the 
second leading worldwide cause of disability 
adjusted life years (the sum of lost life due to 
mortality and years of life adjusted for the 
severity of disability) in industrialized countries 
(Murray, 1997). Based on the above statistics 
there is little doubt that Dyslipidemia is a major 
risk factor for morbidity and mortality. It is thus 
a serious public health problem. 
There are scattered references available 
in Ayurveda correlating Dyslipidemia. Lipids can 
be easily correlated to that of Medo Dhatu. 
Abnormal composition of Medo Dhatu is 
considered as Medo Dosha and subsequently as 
Medoroga. It is a condition caused by 
derangement of Agni in general and 
Medodhatvagni in particular leading to improper 
formation of Medo Dhatu in excess, which 
subsequently starts accumulating in the Srotas 
resulting into obstruction to the flow of Vata, in 
turn aggravating the Vata Dosha which moves 
back into the Pakvashaya causing further 
excitation of Agni requiring frequent meals thus 
the vicious cycle continue resulting into 
Medoroga.[2] 
Statins are the first choice in the 
treatment of Dyslipidemia, however the need for 
long term, lifelong therapy is associated with 
several adverse effects like myopathy, increased 
risk in ARF/CRF, hypothyroidism and memory 
loss. 
In Ayurveda basically treatment is based 
on severity of the disease and virulence of the 
Dosha. Samshodhana (bio cleansing) Chikitsa for 
Bahu Dosha (excessively vitiated Dosha) and 
Samshamana (palliative) Chikitsa for Alpa and 
Madhyama Bala Dosha (mild to moderately 
vitiated Dosha and diseases). Medo roga being 
Bahu Dosha dominant condition Samshodhana 
Chikitsa is preferred treatment modality.  
Among these treatments Basti Karma is 
best treatment for correction of Vata Dosha, 
which is the basic factor involved in the 
pathogenesis of Medoroga. According to Acharya 
Sushruta by using various combinations of 
ingredients it is considered good even in other 
Dosha and Dooshya involvement and beneficial 
in diseases of all the three paths where most of 
them are due to involvement of Vata thus said to 
be Ardha Chikitsa.  
Thus with this thought, A randomised 
clinical study was done to evaluate the efficacy of 
Lekhana Basti in Dyslipidemia. 
AIMS AND OBJECTIVES 
To evaluate the effect of Lekhana Basti in 
the management of Dyslipidemia (Medoroga) 
MATERIALS AND METHODOLOGY 
Patients indicated and fit for trial were 
selected from outpatient and inpatient 
department of Panchakarma, National Institute 
of Ayurveda Hospital, Jaipur, Rajasthan. 
Diagnostic criteria 
1. Abnormal levels of serum lipid profile. 
2. Clinical features of Dyslipidemia and 
Medoroga like Ashaktaha Sarva Karmasu, 
Kshudra Shvasa, Svedadhikya, Utsahahani, 
Angagaurava  
Inclusion criteria 
1. Serum lipid levels ranging  
Serum Cholesterol (201mg/dl or more), 
Serum Triglycerides (161mg/dl or more), Serum 
HDL (below 40mg/dl), Serum LDL (131mg/dl or 
more). Serum VLDL (41mg/dl or more). All or 
any of these.  
2. Having clinical features of Dyslipidemia and 
Medoroga 
Exclusion criteria  
Patients below 20 years & above 60 
years, with other systemic diseases like 
cardiovascular diseases, associated with any 
rectal pathology like Haemarrhoids, Fissure etc., 
not fit for Lekhana Basti were excluded from the 
study. 
Laboratory investigation  
Routine hematological and urine 
investigations, lipid profile, liver function test 
were carried out before and after the treatment. 
Assessment criteria 
 Complete Lipid profile including serum 
cholesterol, serum triglycerides, serum HDL, 
serum LDL, serum VLDL were assessed before 
starting the treatment, after completion of 
treatment and after follow up (As the 
parameters are in the measurements no scoring 
pattern was adopted). 
Lekhana Basti procedure 
In this group Lekhana Basti was 
administered as Kala Basti in modified schedule. 
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Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Basti A N N N A N N N A N N N A N N A 
The Basti was administered in the following steps. 
               The patient was subjected to Sarvanga 
Abhyanga with Dashamoola Taila followed by 
Bashpa Svedana. Then the patient was asked to 
have rice with green gram dal in lesser quantity 
than regular consumption, attend natural urges 
and walk a few steps before reaching the Basti 
room. On the day of Niruha Basti patient was asked 
to come in empty stomach.  
After recording the vitals patient was 
advised to lie comfortably in left lateral position on 
Basti table with left leg straight and the right leg 
flexed at knee and hip joints, head resting on left 
hand with the right hand resting on the right leg. 
Preparation of Basti Dravya  
Anuvasana Basti 
60 ml of Triphala Taila[3] was made 
lukewarm by keeping it in a hot water bath. Then 
Shatapushpa Choorna and Saindhava Lavana (each 
1 gram) added and mixed till a homogenous 
mixture was obtained, again Basti Dravya was luke 
warmed, administered with enema syringe fitted 
with rubber catheter (no.08). 
Niruha Basti[4] 
Makshika (Honey) 60ml, Saindhava Lavana 
5grams, Triphala Taila 90 ml, Yastimadhu Kalka 
20grams, Triphala Kvatha 240ml, were added 
accordingly and stirred well to get homogenous 
mixture. Lastly Gomutra 50ml, Yavakshara and 
Ooshakadi Gana Dravya (Hingu, Tutta, Kaseesa, 
Shilajatu) 2 gram each added administered 
through Basti Putaka. 
Follow up: Follow up of the patients was done 
once in fortnight up to 2 months. 
OBSERVATIONS AND RESULT 
Out of 30 patients maximum 63.33% 
patients were male, 83.33% patients in between 
the age group 25-50 yrs.53.33% patients were 
Hindu, 76.66% patients were married, 80% 
patients were having the history of strainous work, 
53.33%were VataKapha Prakriti, 53% were Kroora 
kosta, 78% patients were non vegetarians. 
Table 1: Showing the effect of treatment on complete lipid profile 
     Pair wise significance 
Lipid Profile BT AT  % AF BT-AT BT-AF AT-AF 
Serum 
Cholesterol 
267.57± 
21.15 
167.17± 
22.10 
37.53% 172.33± 
21.83 
<0.001** <0.001** <0.001** 
Serum 
Triglycerides 
218.83± 
34.25 
166.77± 
22.00 
23.79% 172.23± 
21.30 
<0.001** <0.001** <0.001** 
Serum HDL 56.43± 
8.26 
56.50± 
5.06 
0.12% 58.80± 
5.87 
0.943 0.020* <0.001** 
Serum LDL 167.70± 
14.65 
77.27± 
19.24 
54% 78.62± 
20.36 
<0.001** <0.001** 0.347 
Serum VLDL 43.79± 
6.87 
33.35± 
4.40 
23.85% 34.42± 
4.27 
<0.001** <0.001** <0.001** 
DISCUSSION 
Dyslipidemia can be studied under the 
broad umbrella of Sthaulya in Brihatrayi. 
Atisthaulya is at first mentioned by Acharya 
Charaka as one of the Kaphaja Nanatmaja Vikara in 
Maharoga Adhyaya and is later on elaborated upon 
in the subsequent Ashtau Ninditiya Adhyaya. On 
further contemplation it is evident that Atisthaulya 
is physiology predominant disorder which 
eventually gets converted into a pathological state. 
The progression from a physiology to pathology is 
so prompt that it cannot be pointed out distinctly. 
 A review of the Laghutrayi bears certain 
references to Dyslipidemia. Adhamalla while 
commenting on Sharangdhara Samhita has tried to 
differentiate between the two types Medo Roga viz; 
Sthaulya and Medo Dosha. According to the 
distinction made by him, the former is 
characterized by Udaravriddhi where as the later is 
characterized by morbid changes occurring due to 
obstruction of the channels. 
In the present study a modified Kala Basti 
schedule was adopted, in order to have maximum 
Lekhana effect, more number of Niruha Basti and 
less number of Anuvasana Basti were administered 
as Kala Basti Schedule. The effect of Lekhana Basti 
in Serum Cholesterol can be studied under two 
headings. 
1. Action at the level of Liver 
This could be because of the chief drugs of 
Lekhana Basti like Honey, Triphala, Gomutra, 
Yavakshara, Ooshakadi Gana Dravya are having 
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Kaphahara, Medohara activity which might have 
been absorbed by the superior haemorroidal veins 
reach directly to the liver there by correcting liver 
metabolism which might have reduced the 
synthesis of cholesterol and increasing its 
excretion, and 2/3rd directly enters systemic 
circulation through inferior and middle 
haemorroidal veins resulting into significant 
availability of drugs bypassing first pass 
metabolism which may be the cause in reduction in 
serum level.  
2. Correcting Vata Dosha 
The corner stone in the treatment of 
reducing cholesterol is inhibiting the action of 
Acetyl Co-A reductase which may be considered as 
part of Vata Dosha. Basti Karma regulates the 
production and function of Vata Dosha. 
The effect obtained by Lekhana Basti in 
Serum Triglycerides may be due to the following 
reasons. 
The drugs used in Basti Karma are mainly 
Medohara (hypolipidaemic) and Lekhana in nature 
hence they might have reduced the level of TGL. 
Apart from this the basic causative factor for 
Dyslipidemia (Medoroga) is the abnormal 
movement of Vata Dosha which in turn increases 
the appetite there by in turn result in increased 
calorie intake. Hence to reduce the calorie intake 
the corner stone of the treatment could be 
regulating the movement of Vata Dosha which was 
achieved by successful administration of Basti. 
The improvement in the Serum HDL level 
after the Basti was observed. As Basti Karma 
corrects the Vata Dosha which is responsible for 
the proper transportation of Poshaka Rasa and 
formation of good quality Dhatu.  
Lekhana Basti drugs are having Medohara 
action, it cleanses the channels of transportation 
their by eliminates the accumulated Dosha and 
Malarupi Medo Dhatu which may be the reason for 
the better reduction of Serum LDL and VLDL level. 
 
 
CONCLUSION 
Dyslipidemia is an abnormal amount of 
lipids in the blood due to impaired lipid 
metabolism, can be correlated with abnormal Medo 
Dhatu (Medo Dosha). In Medoroga primarily there 
is Agni Vaishamya and Vata Dushti, among 
Samshodhana Basti Karma is best to correct Vata 
Dosha and further corrects the Agni.  
Lekhana Basti effect showed mean 
decrease of 37.53% in cholesterol, 23.79% in 
triglycerides, 54% in LDL, 23.85% in VLDL and 
increase of 0.12% in HDL levels after the 
treatment. Further after the follow up period 
showed mean reduction of 33.46% in cholesterol, 
20.52% in triglycerides, 52.26% in LDL, 20.65% in 
VLDL and 4.07% of increase in the HDL levels. 
Lekhana Basti was highly effective in reducing of 
cholesterol level which was statistically highly 
significant even after the follow up. 
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